IntroductionDepression is the most common psychiatric illness, with about 121 million people affected worldwide. Of people who experience a depressive episode, 15% commit suicide.1,2 Although many studies have investigated the pathophysiologic mechanisms of major depressive disorder (MDD) using live brain imaging and postmortem studies, its etiology remains unclear; however, recent progress based on those studies has gradually revealed common features of MDD. Among these features, volume reduction of selective brain regions in patients with MDD is the most remarkable.3-5 This is mainly due to a lower number of glial cells and neuronal atrophy in those regions. 6,7 Specifically, the reduction of astrocytes among all glial cells was frequently found in postmortem studies. 3,[8][9][10] Another study reported lower levels of glutamine synthetase (GS), one of the astrocyte-specific enzymes involved in the glutamate-glutamine (Glu-Gln) cycle, and its activity levels were decreased in some clinical studies of MDD.
11A variety of preclinical studies have reported findings to support the idea of astrocyte loss and Glu-Gln disruption. Consistent with those studies, several papers have reported decreased gliogenesis and number of astrocytes in the medial prefrontal cortex (mPFC) in animal models of chronic stressinduced depression.7,12-14 These results strongly suggest that a relationship exists between the functions of astrocytes and the behavioural aspects of MDD. To test this issue, a recent study ablated astrocytes in the prelimbic cortex (PLC) using a specific toxin and revealed that depressive-like behaviours could be evoked using only this treatment.14 It remains to be determined how astrocyte loss results in depressive behaviours.To address this question, we focused on the role of astrocytes Background: The brain levels of glutamate (Glu) and glutamine (Gln) are partially regulated through the Glu-Gln cycle. Astrocytes play a role in regulating the Glu-Gln cycle, and loss of astrocytes has been associated with depressive disorders. We hypothesized that levels of Glu and Gln would be affected by astrocyte loss and dysregulation of the Glu-Gln cycle and that depressive-like behaviours would be closely related to the level of changes in Glu and Gln. Methods: We used liquid chromatography to measure Glu and Gln concentrations in the prefrontal cortex of male mice infused with L-α aminoadipic acid (L-AAA), a specific astrocyte toxin, in the prelimbic cortex. Methionine sulfoximine, a Gln synthetase inhibitor, and α-methyl-amino-isobutyric acid, a blocker of neuronal Gln transporters, were used to disturb the Glu-Gln cycle. We assessed the behavioural change by drug infusion using the forced swim test (FST) and sucrose preference test. Results: The Glu and Gln levels were decreased on the fifth day after L-AAA infusion, and the infused mice showed longer durations of immobility in the FST and lower sucrose preference, indicative of depressive-like behaviour. Mice in which Gln synthetase or Gln transport were inhibited al...